MISTY WITTEN, FNP-C
Family Nurse Practitioner · AUSTIN, TX
Individual Active NPI 1427449305
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 620 | 191,791 | $14,696,997 | $3,935,504 | $3,133,392 |
| 2023 | 577 | 146,842 | $12,171,026 | $3,066,639 | $2,429,327 |
| 2022 | 567 | 130,376 | $12,825,810 | $3,181,942 | $2,525,934 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 49,700 | $1 | $1 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 29,820 | $11 | $8 |
| J0897 | Injection, denosumab, 1 mg | 12,120 | $26 | $20 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 11,400 | $21 | $17 |
| J2182 | Injection, mepolizumab, 1 mg | 7,400 | $29 | $23 |
| J1756 | Injection, iron sucrose, 1 mg | 6,000 | $0 | $0 |
| J2357 | Injection, omalizumab, 5 mg | 4,455 | $38 | $30 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2,530 | $24 | $19 |
| J3245 | Injection, tildrakizumab, 1 mg | 1,800 | $134 | $107 |
| J0517 | Injection, benralizumab, 1 mg | 930 | $165 | $131 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 765 | $0 | $0 |
| 96372 | Injection of drug or substance under skin or into muscle | 763 | $12 | $9 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | AP126050 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in Texas
- NPI 1508783036
- NPI 1093479487
- NPI 1922597699
- NPI 1528524857
- NPI 1518377498
- NPI 1578926440
- NPI 1134842321
- NPI 1992053797
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.